The blood-brain barrier and oncology: New insights into function and modulation

Cancer Treatment Reviews

Volumn 26, Issue 6, 2000, Pages 449-462

  Bart, J ^a   Groen, H J M ^a   Hendrikse, N H ^a   Van der Graaf, W T A ^a   Vaalburg, W ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Blood brain barrier; Brain metastasis; Cytoarchitecture; Modulation; Multidrug resistance; Multidrug resistance associated protein; Organic anion transporter; P glycoprotein; Visualization

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BIRICODAR; BRADYKININ RECEPTOR AGONIST; CARDIOVASCULAR AGENT; CARRIER PROTEIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; GLUCURONIDE; GLUTATHIONE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN; NEW DRUG; OPIATE; PACLITAXEL; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VERLUKAST; ZOSUQUIDAR;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONJUGATION; CYTOARCHITECTURE; CYTOSKELETON; DRUG TRANSPORT; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; ONCOLOGY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIGHT JUNCTION;

EID: 0034500036     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0194     Document Type: Review

References (180)

1. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival
2. The drug resistance-related protein LRP is the human major vault protein
3. Expression of a multidrug-resistance gene in human tumors and tissues
4. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
5. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
6. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography
7. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
8. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
9. Concentration of vinblastine in human intracerebral tumor and other tissues
10. Human central nervous system and plasma pharmacology of mitoxantrone
11. Chemosensitivity of glioma cells in vitro: A meta analysis
12. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery, to gliomas in the rodent: The factor of the blood-brain barrier
13. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone
14. Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?
15. Absence of the mdr 1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
16. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration
17. The response of cerebral metastases in small celllung cancer to systemic chemotherapy
18. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer
19. Functional involvement of P-glycoprotein in blood-brain barrier
20. P-glycoprotein-mediated efflux transport of anti-cancer drugs at the blood-brain barrier
21. Interaction of drugs with P-glycoprotein in brain capillaries
22. The functional role of P-glycoprotein in the blood-brain barrier
23. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
24. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells
25. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
26. Dichotomous development of the organic anion transport protein in liver and choroid plexus
27. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
28. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain
29. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
30. Isolation of a multi-specific organic anion and cardiac glycoside transporter from rat brain
31. Control of brain endothelial permeability
32. Morphometric analysis of CNS microvascular endothelium
33. The cell biology of the blood-brain barrier
34. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail - Chick transplantation chimeras
35. Astrocytes induce blood-brain barrier properties in endothelial cells
36. Cell adhesion, cell junctions and the blood-brain barrier
37. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors
38. Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study
39. Occludin as a possible determinant of tight junction permeability in endothelial cells
40. Ultrastructure of capillary walls in human brain tumors
41. Vascular structures in brain tumors
42. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors
43. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors
44. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor
45. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration
46. Chemotherapy for brain metastases of lung cancer: A review
47. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability
48. In vitro models of the blood-brain barrier to polar permeants: Comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells
49. High levels of P-glycoprotein detected in isolated brain capillaries
50. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine
51. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
52. High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: A potential involvement in protection against carcinogens?
53. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
54. Transporters and the blood-brain barrier (BBB)
55. Disruption of the mouse mdr la P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
56. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug
57. The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdrla (-/-) and mdrla (+/+) mice
58. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
59. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins
60. Visualization of multidrug resistance in vivo
61. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
62. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein
63. Mechanism of action of P-glycoprotein in relation to passive membrane permeation
64. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier
65. ABC transporters: From microorganisms to man
66. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates
67. A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter
68. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain
69. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes
70. Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain
71. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite
72. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
73. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule
74. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus
75. Multidrug resistance gene family and chemical carcinogens
76. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine
77. 17 beta-estradiol glucuronide: An inducer of cholestasis and a physiological substrate for the multidrug resistance transporter
78. Characterization of binding properties to human P-glycoprotein: Development of a [3H]verapamil radioligand-binding assay
79. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents
80. Drug transfer across the blood-brain barrier and improvement of brain delivery
81. How does P-glycoprotein recognize its substrates?
82. Recent progress in P-glycoprotein research
83. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein
84. The multidrug resistance (mdr1) gene product functions as an ATP channel
85. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines
86. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines
87. MRP1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells
88. MRP3, an organic anion transporter able to transport anti-cancer drugs
89. The multidrug resistance protein family
90. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake
91. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells
92. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA
93. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance
94. Tissue distribution of the multidrug resistance protein
95. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line
96. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
97. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein
98. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells
99. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates
100. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2
101. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
102. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
103. Human ATP Binding Cassette transporters
104. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells
105. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain
106. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma
107. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review
108. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors
109. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function
110. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors
111. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7
112. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): Dramatic differences and insight gained from dosing parameters
113. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7)
114. Limited enzymatic digestion for the determination of the quantities of minor diastereomeric impurities in preparations of RMP-7, a peptide containing a reduced peptide bond
115. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy
116. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors
117. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7
118. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: A toxicologic evaluation in swine
119. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma
120. Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin
121. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats
122. Neurologic complications of immunosuppressive agents
123. Cyclosporine A neurotoxicity among bone marrow transplant recipients
124. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation
125. Cyclosporine neurotoxicity: A review
126. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
127. Inhibition of P-glycoprotein: Rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier
128. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma
129. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities
130. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
131. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
132. Modulation of multidrug resistance (MDR) in hematological malignancies
133. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
134. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukamia (AML) patients 60 years (CALGB 9720)
135. Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells
136. Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man
137. Biricodar (VX-710; Incel): An effective chemosensitizer in neuroblastoma
138. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P
139. The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells
140. d,l-buthionine-(S,R)- sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors
141. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione
142. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer
143. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp)
144. Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein
145. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction
146. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines
147. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats
148. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi
149. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant
150. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
151. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier
152. Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation
153. Development of blood vessel-related radiation damage in the fimbria of the central nervous system
154. Disruption of the blood-brain barrier as the primary effect of CNS irradiation
155. Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain
156. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium
157. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy
158. The entry of antiviral and antiretroviral drugs into the central nervous system
159. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
160. Delivery of anti-HIV nucleosides to the central nervous system
161. The ins and outs of antiviral drug transport in the brain
162. Resistance of HIV to antiretroviral agents. Basic concepts
163. Neurological complications of organ transplantation
164. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression
165. Cyclosporine
166. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases
167. Late onset of neurotoxicity with cyclosporin
168. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice
169. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution
170. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
171. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
172. Multidrug resistance: Molecular mechanisms and clinical relevance
173. Active transport of fentanyl by the blood-brain barrier
174. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells
175. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat
176. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486
177. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein
178. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro
179. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter
180. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP